INTRODUCTION {#sec1-1}
============

Understanding the genetic pathways involved in pharmacokinetics and pharmacodynamics of the drugs can have a substantial effect on the personalized treatment of the patients.\[[@ref1]\] Differences in patients' response to drug treatment are partly due to individual differences in genetic constitution such as genes encoding drug-metabolizing enzymes.\[[@ref2][@ref3]\] Cytochrome P450 2D6 (CYP2D6) is one of the most important drug-metabolizing enzymes implicated in the metabolism of many clinical drugs such as antipsychotic drugs, antiarrhythmic agents, tricyclic antidepressants, β-blockers opioids, and anticancer drugs.\[[@ref4][@ref5]\] The *CYP2D6* is a highly polymorphic gene, with more than 100 allelic variants being currently reported for.\[[@ref6]\] The combination of different alleles yields different phenotypes such as extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) which have normal, reduced, and no activity of the enzyme, respectively.\[[@ref7][@ref8]\] The doubling of the gene that produces an enzyme with increased activity is also called the ultrarapid metabolizer (UM).\[[@ref9][@ref10]\] Interindividual differences in the kinetic characteristics of the drugs are partly attributed to the presence of alleles with altered activity.\[[@ref11]\] Human variability in the kinetics of CYP2D6 substrates has been shown for different compounds metabolized extensively (\>60%) by this polymorphic enzyme.\[[@ref12]\]

Due to the effect of the CYP2D6 enzyme activity on drug metabolism, genetic studies of the gene in different populations are needed to determine the frequency of alleles in each ethnic group. This will help choose the effective treatment for the patients based on the genotype. The current study reviews the allele and genotype frequencies of *CYP2D6* in the Middle East region. We searched in PubMed and Google Scholar from 1996 to 2017 using the combination of keywords such as *CYP2D6*, allele, and frequency plus the name of each country in the Middle East region. All studies reported *CYP2D6* allele and genotype frequencies in different Middle Eastern countries including Saudi Arabia,\[[@ref13][@ref14]\] Egypt,\[[@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21]\] United Arab Emirates (UAE),\[[@ref22][@ref23]\] Iran,\[[@ref24][@ref25][@ref26][@ref27]\] Jordan,\[[@ref28]\] Syria,\[[@ref29]\] and Turkey\[[@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43][@ref44][@ref45]\] performed on healthy unrelated controls or patient samples were reviewed in this article. Overview of the studies evaluated in this review is listed in [Table 1](#T1){ref-type="table"}, showing the number of studies in each geographic region, number and type of samples (healthy or patients), list of alleles considered, and their frequency in each study.

###### 

Overview of the studies evaluated in this review

  Country (reference)        Number of individuals (*n*)   Subject type                                                         Functional alleles   Reduced functional alleles   Nonfunctional alleles   Duplications                                        
  -------------------------- ----------------------------- -------------------------------------------------------------------- -------------------- ---------------------------- ----------------------- -------------- ------ -------- ------ ------ ------ ------
  Saudi Arabia\[[@ref14]\]   101                           Healthy                                                              79.1                 N/A                          3                       3              N/A    N/A      3.5    1      N/A    10.4
  Saudi Arabia\[[@ref13]\]   192                           Healthy                                                              78.4                 N/A                          N/A                     N/A            18.4   0        N/A    N/A    0      N/A
  Egypt\[[@ref15]\]          21+22                         Healthy + bladder cancer                                             47.7                 N/A                          N/A                     N/A            N/A    52.3\*   N/A    N/A           
  Egypt\[[@ref16]\]          27+37                         Healthy + bladder cancer                                             54.7                 N/A                          N/A                     N/A            N/A    45.3\*   N/A    N/A           
  Egypt\[[@ref17]\]          429+123                       Healthy + hypertensive cases                                         85.1                 N/A                          N/A                     N/A            N/A    14.9\*   N/A    N/A           
  Egypt\[[@ref18]\]          11+32                         Healthy + acute leukemia                                             53.5                 N/A                          N/A                     N/A            N/A    N/A      46.5   N/A    N/A    N/A
  Egypt\[[@ref20]\]          308                           Healthy fertile and infertile                                        74.4                 N/A                          N/A                     N/A            N/A    N/A      25.6   N/A    N/A    N/A
  Egypt\[[@ref21]\]          29+30                         Healthy + chronic organophosphate exposed patients                   78                   N/A                          N/A                     N/A            N/A    N/A      22     N/A    N/A    N/A
  Egypt\[[@ref19]\]          29+40                         Healthy + acute organophosphate exposed patients                     81.9                 N/A                          N/A                     N/A            N/A    N/A      18.1   N/A    N/A    N/A
  Iran\[[@ref25]\]           100                           Healthy                                                              43.5                 32                           9                       0              N/A    N/A      12.5   3      N/A    N/A
  Iran\[[@ref26]\]           100                           Healthy                                                              90                   N/A                          N/A                     N/A            N/A    0.5      9      N/A    0.5    N/A
  Iran\[[@ref27]\]           101                           Breast cancer                                                        63.4                 N/A                          N/A                     N/A            N/A    N/A      36.6   N/A    N/A    N/A
  Iran\[[@ref24]\]           300                           Healthy                                                              68.2                 N/A                          31.8                    N/A            N/A    N/A      0      N/A    N/A    N/A
  Turkey\[[@ref34]\]         80+32                         Healthy + SLE patients                                               85.3                 N/A                          N/A                     N/A            N/A    0.4      14.3   N/A    N/A    N/A
  Turkey\[[@ref41]\]         53                            Ankylosing spondylitis patients                                      84                   N/A                          N/A                     N/A            N/A    N/A      16     N/A    N/A    N/A
  Turkey\[[@ref45]\]         100                           Healthy                                                              69                   N/A                          14.5                    N/A            N/A    1        10     3      2.5    N/A
  Turkey\[[@ref44]\]         55+132                        Healthy + epileptic children patients                                81.8                 N/A                          N/A                     N/A            N/A    0.8      17.4   N/A    N/A    N/A
  Turkey\[[@ref43]\]         30+60                         Responsive and nonresponsive FMF patients                            55                   N/A                          N/A                     N/A            N/A    4.2      15.8   2.5    22.5   N/A
  Turkey\[[@ref42]\]         140+155+94                    Healthy + ALL + AML                                                  82.8                 N/A                          N/A                     N/A            N/A    1.3      15.9   N/A    N/A    N/A
  Turkey\[[@ref35]\]         249                           Turkey with symptoms of arthritis, sacroiliac, joint and back pain   87.8                 N/A                          N/A                     N/A            N/A    N/A      12.2   N/A    N/A    N/A
  Turkey\[[@ref32]\]         160                           Healthy                                                              81                   N/A                          N/A                     N/A            15     N/A      N/A    N/A    N/A    N/A
  Turkey\[[@ref31]\]         128+135                       Healthy + breast cancer patients                                     66.3                 N/A                          N/A                     N/A            N/A    N/A      33.7   N/A    N/A    N/A
  Turkey\[[@ref38]\]         52+100                        Healthy + ankylosing spondylitis patients                            83.9                 N/A                          N/A                     N/A            N/A    N/A      16.1   N/A    N/A    N/A
  Turkey\[[@ref33]\]         140                           Healthy                                                              83.6                 N/A                          N/A                     N/A            N/A    2.5      13.9   N/A    N/A    N/A
  Turkey\[[@ref40]\]         404                           Healthy                                                              37.06                35.3                         6.06                    1.11           N/A    0        11.3   1.49   0.74   1.98
  Turkey\[[@ref37]\]         100                           Healthy                                                              79                   N/A                          N/A                     N/A            N/A    N/A      21     N/A    N/A    N/A
  Turkey\[[@ref36]\]         92                            Breast cancer patients                                               42.4                 19.6                         6                       0.6            15.2   1.6      10.3   1.1    1.6    N/A
  Turkey\[[@ref39]\]         200                           Healthy                                                              32                   35                           26                      N/A            N/A    6        1      N/A    N/A    N/A
  Turkey\[[@ref30]\]         251                           Migraine patients                                                    81.9                 N/A                          N/A                     N/A            N/A    0.4      17.7   N/A    0      N/A
  Emirates\[[@ref23]\]       50+101                        Healthy + antidepressants                                            39.1                 12.2                         3.3                     2.5            15.2   N/A      9      N/A    N/A    4.3
  Syria\[[@ref29]\]          51                            Healthy                                                              47.07                30.39                        2.94                    0              N/A    0        9.8    0.98   0.98   3.92
  Jordan\[[@ref28]\]         192                           Healthy                                                              50.6                 N/A                          14.8                    8.3            N/A    N/A      12.8   N/A    N/A    13.5

\*Related to the \*3, \*4, and \*5 together. ALL=Acute lymphoid leukemia; AML=Acute myeloid leukemia; FMF=Familial Mediterranean fever; SLE=Systemic lupus erythematous; N/A=Not applicable

DISTRIBUTION OF THE CYTOCHROME P450 2D6 ALLELIC FREQUENCIES IN THE MIDDLE EAST {#sec1-2}
==============================================================================

In the present study, alleles were assigned according to the nomenclature for human *CYP2D6* alleles.\[[@ref46]\] The examined alleles were classified according to their function labeled with functional, reduced, nonfunctional, and duplications. The average frequency of the *CYP2D6* alleles in each country is shown in [Figure 1](#F1){ref-type="fig"}.

![The allelic frequency of different cytochrome P450 2D6 alleles in the Middle Eastern countries. The frequency of the alleles with \<3% accumulated in the other part of each chart. For each allele in each country, the results of studies that examined the relevant allele have been reported in the mean](JRMS-24-61-g001){#F1}

The two functional frequent alleles, 2D6\*1 or \*2, were considered in some previous studies if no variants were found.\[[@ref47]\] However, now, the \*1 and \*2 alleles can be distinguished from one another through the examination of the missense mutation of rs1135840 (4180G\>C) for \*2 assignment, and 2D6\*1 could be assigned if no variants encountered. In the Middle Eastern population studied here, the frequency of *CYP2D6*\*2 was evaluated in different studies in Iran, UAE,\[[@ref23]\] and Syria\[[@ref29]\] with the frequency of 32%, 12.2%, and 30.39%, respectively, and average frequency of 29.7% in three studies in Turkey.\[[@ref36][@ref39][@ref40]\] In these studies, apart from the *CYP2D6*\*1 allele, the *CYP2D6*\*2 was the most abundant allele in the population, except for the UAE,\[[@ref23]\] in which the frequency of *CYP2D6*\*41 was reported to be more than *CYP2D6*\*2. Furthermore, in the UAE,\[[@ref23]\] other normal alleles such as *CYP2D6*\*27, \*34, \*35, \*39, \*43, and \*46 were also examined with the frequency of 0.7%, 1%, 2%, 4%, 0.3%, and 0.3%, respectively. For all of the populations reviewed here, *CYP2D6*\*1 allele frequency was calculated accordingly as shown in [Table 1](#T1){ref-type="table"}.

Of the reduced functional alleles, the *CYP2D6*\*41 was presented in Saudi Arabia,\[[@ref13]\] UAE,\[[@ref23]\] and Turkey\[[@ref32][@ref36]\] with the frequency of 18.4%, 15.2%, and 15.1%, respectively. In these populations, the *CYP2D6*\*41 had the highest frequency between the reduced functional alleles. In terms of *CYP2D6*\*10 allele frequency, Iran\[[@ref24][@ref25]\] had the highest rate (20.4%), followed by Jordan\[[@ref28]\] and Turkey\[[@ref36][@ref39][@ref40][@ref45]\] with 14.8% and 13.14% frequency, respectively. Finally, UAE,\[[@ref23]\] Saudi Arabia,\[[@ref14]\] and Syria\[[@ref29]\] with the frequency of 3.3%, 3%, and 2.94%, respectively, ranked the last. The *CYP2D6*\*29 allelic frequency had only been reported in the populations of Saudi Arabia\[[@ref13]\] and the UEA,\[[@ref23]\] with a frequency of 2.9% and 1.6%, respectively. The *CYP2D6*\*17 allele was absent in the population of Iran\[[@ref25]\] and Syria,\[[@ref29]\] but this allele was reported with a frequency of 3%, 2.5%, and 0.85% in Saudi Arabia,\[[@ref14]\] UAE,\[[@ref23]\] and Turkey,\[[@ref36][@ref40]\] with the highest frequency being in the Jordan\[[@ref28]\] population (8.3%). In addition, the presence of the *CYP2D6*\*9 was reported only in the two Turkish populations\[[@ref32][@ref40]\] at a frequency of 2.31%.

Of nonfunctional alleles, a low frequency of *CYP2D6*\*7 was only observed in Turkey,\[[@ref36][@ref40]\] *CYP2D6*\*14 in Saudi Arabia,\[[@ref13]\] and *CYP2D6*\*3 in Iran\[[@ref26]\] and Turkey.\[[@ref33][@ref34][@ref42][@ref43][@ref44][@ref45]\] Furthermore, *CYP2D6*\*5 and *CYP2D6*\*6 showed the highest frequency in the Iranian\[[@ref25]\] and Turkish\[[@ref30][@ref36][@ref40][@ref43][@ref45]\] populations, respectively. The *CYP2D6*\*4 allele had the highest frequency of 28.05% in Egypt\[[@ref18][@ref19][@ref20][@ref21]\] and the lowest frequency of 3.5% in Saudi Arabia\[[@ref14]\] (3.5%). Between these two intervals, Turkey, Iran, Jordan, Syria, and UAE had the *CYP2D6*\*4 abundance of 15.1%, 14.5%, 12.8%, 9.8%, and 9%, respectively. In Egypt, although some studies\[[@ref18][@ref19][@ref20][@ref21]\] showed only the frequency of \*4 among nonfunctional alleles, three studies\[[@ref15][@ref16][@ref17]\] reported the frequency of \*3, \*4, and \*5 together. We averaged all of them for reporting nonfunctional alleles in the Egyptian population \[[Figure 1](#F1){ref-type="fig"}\].

Among the countries that gene duplication had been studied, Turkey\[[@ref40]\] showed the least frequent and Saudi Arabia\[[@ref14]\] indicated the highest.

VARIABILITY OF THE CYTOCHROME P450 2D6 PHENOTYPE FREQUENCIES PREDICTED FROM GENOTYPES IN THE MIDDLE EAST {#sec1-3}
========================================================================================================

EM (individuals with at least one functional allele), IM (individuals with a combination of two decreased function variants or a combination of one nonfunctional allele with a functional or reduced function variants), PM (individuals with two nonfunctional variants), and UM (individuals with more than two functional alleles) phenotype frequencies were evaluated in a study by Ingelman-Sundberg *et al.*\[[@ref48]\] Summary of the *CYP2D6* phenotype frequencies in each country is shown in [Figure 2](#F2){ref-type="fig"}.

![The genotype frequency of cytochrome P450 2D6 in different Middle Eastern countries. EM; IM; PM; and UM; frequencies was presented in the chart for each country, separately. EM = Extensive metabolizer; IM = Intermediate metabolizer; PM = Poor metabolizer; and UM = Ultrarapid metabolizer](JRMS-24-61-g002){#F2}

Differentiating by ethnic groups, the EM frequency is found to be higher in Saudi Arabia than other countries. It is of note that Egyptian showed the highest PM and IM frequency among Middle East populations. Furthermore, UM frequency varies widely among different populations of the Middle East, with the highest frequency in Saudi Arabians.

DISCUSSION {#sec1-4}
==========

In a previously reviewed study\[[@ref49]\] of the *CYP2D6* allele frequencies worldwide, the Middle East was mentioned as a single area, but different countries in the Middle East were not evaluated separately. Interestingly, the result of our study in the Middle East as a whole was different from the previous one in some of *CYP2D6* allele frequencies. Two of the most frequent alleles in the present study, *CYP2D6*\*4 and \*10, had been reported with less frequency in the previous study. These differences may be because limited parts of the Middle East were evaluated in the previous study, not including all the countries. Other allele frequencies were approximately the same in the two studies.

Frequency of *CYP2D6* alleles in various regions of the Middle East is different. These different results are due to the different ethnic groups and different methods used. Of note, most of the articles studied here used polymerase chain reaction (PCR) restriction fragment length polymorphism (PCR-RFLP) method for determining the *CYP2D6* alleles, and other methods such as real-time PCR, allele-specific PCR, and sequencing were used less. Hence, ethnic differences seem to be more important in presenting different allelic frequencies than the discrepancy of the methods used.

Here, the comparison of the frequency of different *CYP2D6* alleles in the Middle East with Asia, Africa, America, and Europe had been discussed. The incidence of *CYP2D6*\*2 allele in the Middle East appeared to be as frequent as that in Americans (23.48%), Europeans (26.91%), and South/Central Asians (31.90%),\[[@ref10]\] whereas lower frequencies of this allele were reported among Africans (17.13%) and Asians (12.82%).\[[@ref9]\]

The allelic frequency of *CYP2D6*\*10 in the Middle East was higher than Africans (5.47%), Americans (3.37%), and Europeans (3.16%), but much lower than those reported for Asians (42.31%). Unlike Asia, the prevalence of IM alleles mostly contributed to *CYP2D6*\*41 (15.95%). There were no published studies on the prevalence of this allele in the Iranian ethnic populations. The *CYP2D6*\*41 allele frequency in the Middle East was higher than that found in the Africans (10.18%), Europeans (8.56%), South/Central Asians (10.5%), Americans (5.93%), and Asians (1.97%). In addition, the *CYP2D6*\*17 allele frequency was higher than that reported in the Europeans (0.32%) and South/Central Asians (0.38%), but much lower than Africans (19.1%). Furthermore, the allelic frequency of *CYP2D6*\*9 in our study was comparable with Americans (1.32%) and South/Central Asians (1.4%), but lower than Europeans (2.4%) and higher than Africans (0.3%) and Asians (0.07%).\[[@ref9]\]

The allelic frequency of *CYP2D6*\*3 in the Middle East was higher than that reported for Africans (0.17%) and Americans (0.73%), but was comparable with that found in the Europeans (1.2%). The allelic frequency of *CYP2D6*\*4 in our samples was higher than that reported for Africans (4.8%), Asians (0.4%), Americans (11.3%), and South/Central Asians (6.6%), but was lower than those reported for Europeans (18.5%). Few studies had been conducted on the frequency of the *CYP2D6*\*6 allele; nonetheless, the frequencies of this allele in Africans, Americans, Asians, and Europeans were reported to be 0.24%, 0.43%, 0.02% and 0.95%, respectively. The allelic frequency of *CYP2D6*\*5 was comparable to Americans (1.9%), but lower than Africans (6.11%), Asians (5.61%), Europeans (2.69%), and South/Central Asians (2.54%). Our allelic frequency of *CYP2D6*\*5 was higher than that reported in Europeans (0.11%). The \*14 allelic frequency in our study was lower than Africans (0.26%), Americans (0.33%), Asians (5.61%), Europeans (2.69%), and South/Central Asians (2.54%).\[[@ref9]\]

CONCLUSION {#sec1-5}
==========

Taken together, our study on the allelic frequency of *CYP2D6* in the Middle East demonstrated that allele \*4 is the most frequent PM allele in this region as well as other parts of the world. In case of IM alleles, the allele \*41 is the most common allele in the populations, of which the \*41 allele frequency was evaluated. However, in other populations, like the rest of the world, the most abundant allele is \*10. Observing the different allelic frequencies of *CYP2D6* gene in this region, these results should be considered in the application of the treatment protocol.
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